Archive: 01/04/2019
LOXO-195 promising against tumors with acquired resistance to first-generation therapeutics
The investigational anticancer therapeutic LOXO-195 (now known as BAY 2731954), which targets a family of proteins called TRKs, was safe, tolerable, and showed signs of clinical activity in patients who had solid tumors that ...
Apr 1, 2019